Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Cancer Research","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Touchlight","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cancer Research","sponsor":"BioInvent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioInvent Streamlines Agreement on Anti-Fc\u03b3 Rll B Antibody, BI-1206, Ahead of Phase I\/II Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Teon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cancer Research UK and Teon Therapeutics Advance New First-in-Class Cancer Drug Into Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Aleta Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aleta Biotherapeutics and Cancer Research UK Collaborate to Advance Blood Cancer Therapy Into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cancer Research UK and Sosei Heptares Sign Agreement to Advance Cancer Immunotherapy Candidate Into Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Lineage Cell Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results with VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Sosei Heptares","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I\/IIa Trial with Cancer Immunotherapy Drug HTL0039732","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Cancer Research

    Menu

    Cancer Research

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cancer Research

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

              Details:

              HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies.

              Lead Product(s): HTL0039732,Atezolizumab

              Therapeutic Area: Oncology Product Name: HTL0039732

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Recipient: Sosei Heptares

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cancer Research

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results with VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer

              Details:

              AST-VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells.

              Lead Product(s): AST-VAC2

              Therapeutic Area: Oncology Product Name: AST-VAC2

              Highest Development Status: Phase I Product Type: Vaccine

              Recipient: Lineage Cell Therapeutics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 24, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cancer Research

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cancer Research UK and Sosei Heptares Sign Agreement to Advance Cancer Immunotherapy Candidate Into Clinical Trials

              Details:

              Under the Clinical Trial and Licence Agreement (CTLA), Cancer Research UK’s Centre for Drug Development will sponsor, design and execute a Phase I/IIa clinical trial of HTL00397322, a novel selective EP4 antagonist.

              Lead Product(s): HTL0039732

              Therapeutic Area: Oncology Product Name: HTL0039732

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Sosei Group Corporation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cancer Research

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IDEAYA Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for E...

              Details:

              Following the option exercise, IDEAYA holds exclusive worldwide license rights covering a broad class of PARG inhibitors. IDEAYA owns all commercial rights in IDE161, subject to economic obligations, worldwide license with Cancer Research UK and University of Manchester.

              Lead Product(s): IDE161

              Therapeutic Area: Oncology Product Name: IDE161

              Highest Development Status: IND Enabling Product Type: Small molecule

              Recipient: Ideaya Biosciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cancer Research

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aleta Biotherapeutics and Cancer Research UK Collaborate to Advance Blood Cancer Therapy Into the Clinic

              Details:

              Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase 1/2a clinical trial of ALETA-001, which will be led by Dr Amit Patel’s Cellular and CAR-T therapies team at The Christie NHS Foundation Trust in Manchester, UK.

              Lead Product(s): ALETA-001

              Therapeutic Area: Oncology Product Name: ALETA-001

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Recipient: Aleta Biotherapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cancer Research

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cancer Research UK and Teon Therapeutics Advance New First-in-Class Cancer Drug Into Clinical Trial

              Details:

              The partnership focuses on Teon’s potentially first-in-class small molecule adenosine A2B receptor antagonist TT-702, for the treatment of multiplecancers including prostate and triple-negative breast.

              Lead Product(s): TT-702

              Therapeutic Area: Oncology Product Name: TT-702

              Highest Development Status: IND Enabling Product Type: Small molecule

              Recipient: Teon Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cancer Research

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioInvent Streamlines Agreement on Anti-Fcγ Rll B Antibody, BI-1206, Ahead of Phase I/II Data

              Details:

              BioInvent is conducting a Phase I/II trial of BI-1206 in combination with rituximab to treat NHL. CRUK decided to end the trial being conducted in the UK after the single-agent part of the study. Both parties have agreed to restructure their agreement concerning BI-1206.

              Lead Product(s): BI-1206,Rituximab

              Therapeutic Area: Oncology Product Name: BI-1206

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Recipient: BioInvent

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cancer Research

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine

              Details:

              The new clinical development partnership aims at progressing a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).

              Lead Product(s): TGL-100

              Therapeutic Area: Oncology Product Name: TGL-100

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Touchlight

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership July 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cancer Research

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration

              Details:

              The expanded research collaboration will evaluate IDEAYA's PARG inhibitors in vitro in multiple ovarian cancer cell lines and in vivo in ovarian cancer xenograft models.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ideaya Biosciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY